Editas Medicine, Inc. - Multiplikator Forward P/S EDIT

editasmedicine.com - logo grafis emiten EDIT

Binary risks associated with CRISPR clinical trials have triggered high volatility, and the forward P/S ratio dynamics on GURU.Markets are available to analyze this spike, where the 5.80 mark records this metric for Editas Medicine, Inc. (EDIT). Market capitalization relies on partner payments, while gene synthesis combines automation with the expertise of leading scientists.

editasmedicine.com - Multiplikator forward rega marang pendapatan EDIT (periode 04.07.2022 - 17.11.2026)

Editas Medicine, Inc. - rincian analitis lan metrik utama (EDIT)

Analisis wiwitan perusahaan:Editas (EDIT)
Produk asli Editas Corp

The forward P/S ratio compares the current market capitalization of Editas Medicine, Inc. (EDIT) with expected sales volume, making it possible to distinguish asset undervaluation from a systemic business decline. By analyzing the projected price-to-sales ratio, an investor can assess the extent to which the market has priced in the company's transition toward intellectual property licensing and in-vivo technologies to avoid a value trap during a price decline.

Pesaing wigati

Multiplikator Forward P/S TEM (Tempus Labs)|Qiagen N.V. - Rasio rega marang prakiraan pendapatan|IONS - Rasio rega marang prakiraan pendapatan|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep repligen.com|RNA: Multiplikator Forward P/S|CRISPR Therapeutics Inc (CRSP) - Multiplikator Forward P/S|WGS (GeneDx Holdings) - Multiplikator Forward P/S|RARE: Rega forward marang dodolan|Multiplikator forward rega marang pendapatan BEAM (Beam Therapeutics Corp)|SRPT: Rega mangsa ngarep marang pendapatan|Multiplikator Forward P/S TWST (Twist Bioscience Inc)|Rasio kapitalisasi marang dodolan sing dikarepake 10x Genomics Corp (TXG)|intelliatx.com - Multiplikator Forward P/S|Rasio kapitalisasi marang dodolan sing dikarepake Stoke STOK|biolifesolutions.com (BLFS) - Rasio rega marang prakiraan pendapatan|WVE - Rasio kapitalisasi marang dodolan sing dikarepake|Multiplikator forward rega marang pendapatan MAZE|Multiplikator forward rega marang pendapatan Sionna Therapeutics, Inc. (SION)|Multiplikator forward rega marang pendapatan PRME (Prime Medicine Bio)|Rasio kapitalisasi marang dodolan sing dikarepake Taysha|uniQure Pharma - Multiplikator forward rega marang pendapatan|MeiraGTx Holdings plc - Rasio rega marang prakiraan pendapatan|regenxbio.com - Multiplikator Forward P/S|Solid Bio (SLDB) - Multiplikator forward rega marang pendapatan|OCGN: Multiplikator Forward P/S|Multiplikator forward rega marang pendapatan Pacific Biosciences of California|BNTC (Benitec Biopharma Inc.) - Multiplikator Forward P/S|Kapitalisasi marang prakiraan pendapatan DSGN (Design Therapeutics)|Multiplikator Forward P/S RCKT|Rasio rega marang prakiraan pendapatan FDMT (4D Molecular Therapeutics Inc)|Multiplikator Forward P/S LXEO (Lexeo Therapeutics Inc.)|Rega forward marang dodolan KRRO|SLN - Rasio rega marang prakiraan pendapatan|Prakiraan rega marang pendapatan ProQR Therapeutics (PRQR)|CDXS (Codexis Bio) - Multiplikator forward rega marang pendapatan|Sangamo Therapeutics Inc. (SGMO) - Multiplikator Forward P/S|Rasio rega marang prakiraan pendapatan Nautilus Bio|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep Metagenomi Therapeutics MGX|Rasio rega marang prakiraan pendapatan Precision BioSciences (DTIL)|GBIO - Rasio kapitalisasi pasar marang pendapatan mangsa ngarep|Multiplikator Forward P/S BOLD (Boundless Bio, Inc)|XCUR - Multiplikator forward rega marang pendapatan|IMNN - Rasio rega marang prakiraan pendapatan|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep Phio Pharmaceuticals Corp|MBIO: Multiplikator Forward P/S|TransCode (RNAZ) - Multiplikator Forward P/S|BNGO (Bionano) - Multiplikator Forward P/S|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep Applied DNA Sciences, Inc. APDN|Multiplikator Forward P/S BLUE|ImmunoPrecise Antibodies Ltd - Kapitalisasi marang prakiraan pendapatan|Rasio rega marang prakiraan pendapatan Omega Therapeutics OMGA|OMIC: Kapitalisasi marang prakiraan pendapatan|RGLS: Multiplikator forward rega marang pendapatan|Rega forward marang dodolan SYRS (Syros Pharmaceuticals, Inc.)|Telesis Bio, Inc. (TBIO) - Rasio rega marang prakiraan pendapatan|Rega mangsa ngarep marang pendapatan TCON (TRACON)|Rasio rega marang prakiraan pendapatan Unity Biotechnology, Inc.